Impact of Delaying the Addition of Anti-EGFR in First Line of
RAS Wild-Type Metastatic Colorectal Cancer: A
Propensity-Weighted Pooled Data Analysis

J 2022

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA et. al.

Základní údaje

Originální název

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

Autoři

PALMIERI, Lola-Jade, Tomas BUCHLER (203 Česká republika), Antoine MEYER, Veronika VESKRNOVA (203 Česká republika), Ondrej FIALA (203 Česká republika), Petr BRABEC (203 Česká republika, domácí), Jana BARANOVÁ (703 Slovensko, domácí) a Romain CORIAT (garant)

Vydání

Cancers, BASEL, MDPI, 2022, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Kód RIV

RIV/00216224:14110/22:00128223

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers14061410

UT WoS

000776818400001

Klíčová slova anglicky

metastatic colorectal cancer; RAS status; anti-EGFR; bevacizumab

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 1. 2023 13:04, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor antibodies is commonly delayed because of late RAS testing results. Our objective was to evaluate the impact on the overall survival of delayed anti-EGFR introduction strategy. This study compared 305 patients with delayed anti-EGFR introductions, 401 with immediate anti-EGFRs, and 129 with immediate anti-VEGFs. The study suggests that delayed introduction has no deleterious impact on survival compared to the immediate introduction of an anti-EGFR or of an anti-VEGF. The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.

Citovat

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA, Petr BRABEC, Jana BARANOVÁ a Romain CORIAT. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. Cancers. BASEL: MDPI, 2022, roč. 14, č. 6, s. 1-10. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14061410.

@article{2249114,
   author = {Palmieri, LolaandJade and Buchler, Tomas and Meyer, Antoine and Veskrnova, Veronika and Fiala, Ondrej and Brabec, Petr and Baranová, Jana and Coriat, Romain},
   article_location = {BASEL},
   article_number = {6},
   doi = {http://dx.doi.org/10.3390/cancers14061410},
   keywords = {metastatic colorectal cancer; RAS status; anti-EGFR; bevacizumab},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis},
   url = {https://www.mdpi.com/2072-6694/14/6/1410},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2249114
AU  - Palmieri, Lola-Jade - Buchler, Tomas - Meyer, Antoine - Veskrnova, Veronika - Fiala, Ondrej - Brabec, Petr - Baranová, Jana - Coriat, Romain
PY  - 2022
TI  - Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
JF  - Cancers
VL  - 14
IS  - 6
SP  - 1-10
EP  - 1-10
PB  - MDPI
SN  - 20726694
KW  - metastatic colorectal cancer
KW  - RAS status
KW  - anti-EGFR
KW  - bevacizumab
UR  - https://www.mdpi.com/2072-6694/14/6/1410
N2  - Simple Summary The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor antibodies is commonly delayed because of late RAS testing results. Our objective was to evaluate the impact on the overall survival of delayed anti-EGFR introduction strategy. This study compared 305 patients with delayed anti-EGFR introductions, 401 with immediate anti-EGFRs, and 129 with immediate anti-VEGFs. The study suggests that delayed introduction has no deleterious impact on survival compared to the immediate introduction of an anti-EGFR or of an anti-VEGF. The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.
ER  -

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA, Petr BRABEC, Jana BARANOVÁ a Romain CORIAT. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. \textit{Cancers}. BASEL: MDPI, 2022, roč.~14, č.~6, s.~1-10. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14061410.

Podrobný výpis o publikaci